Equities research analysts expect Aerie Pharmaceuticals Inc (NASDAQ:AERI) to announce earnings per share (EPS) of ($0.87) for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.88) and the highest is ($0.86). Aerie Pharmaceuticals reported earnings of ($1.14) per share during the same quarter last year, which indicates a positive year over year growth rate of 23.7%. The business is scheduled to issue its next earnings report after the market closes on Wednesday, August 7th.
According to Zacks, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.69) per share for the current fiscal year, with EPS estimates ranging from ($2.92) to ($2.34). For the next year, analysts expect that the company will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.86) to $0.03. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, May 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.13. The firm had revenue of $10.85 million for the quarter, compared to the consensus estimate of $12.66 million. Aerie Pharmaceuticals had a negative net margin of 684.56% and a negative return on equity of 93.96%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Truvestments Capital LLC purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $33,000. Quantamental Technologies LLC purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $41,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $47,000. Meeder Asset Management Inc. raised its holdings in shares of Aerie Pharmaceuticals by 134.0% during the first quarter. Meeder Asset Management Inc. now owns 1,060 shares of the company’s stock valued at $50,000 after purchasing an additional 607 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in shares of Aerie Pharmaceuticals during the fourth quarter valued at approximately $105,000.
Shares of NASDAQ AERI traded up $0.15 during midday trading on Friday, hitting $21.59. The stock had a trading volume of 913,351 shares, compared to its average volume of 832,626. The firm’s 50 day moving average is $26.57. The stock has a market cap of $991.41 million, a P/E ratio of -4.64 and a beta of 0.42. Aerie Pharmaceuticals has a 52 week low of $20.88 and a 52 week high of $67.65. The company has a current ratio of 3.47, a quick ratio of 3.27 and a debt-to-equity ratio of 0.06.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Story: How to trade on quiet period expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.